Official Title
A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Brief Summary

The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission with incomplete hematologic recovery [CRi], complete remission with incomplete platelet recovery [CRp]) with MRD without access to comparable or alternative therapy.

Detailed Description

The United States Food and Drug Administration (FDA), the Japanese Ministry of Health, Labour
and Welfare (MHLW) and Health Canada have approved ASP2215/Gilteritinib (XOSPATA®) for the
treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with
a FLT3 mutation.

This treatment protocol is being conducted while phase 3 ASP2215 studies are ongoing in
FLT3-mutated AML subjects.

Subjects will complete visits on cycle 1 - days 1, 4, 8, 15; cycle 2 - days 1, 15; cycles 3
to 6 - day 1; and day 1 of every 2 cycles thereafter (i.e., cycle 8 day 1, cycle 10 day 1,
etc.) until discontinued from the study.

Subjects will be provided with study medication until the investigator determines the subject
is no longer receiving clinical benefit.

An end of treatment visit will be performed within 7 days after last dose of investigational
product (ASP2215), or prior to initiation of another anticancer therapy, whichever occurs
earlier, followed by a 30-day follow-up. [Specific to investigational sites in Japan: Study
population does not include subjects with FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD.
Hence, efficacy (MRD response rate and duration of response) data will not be collected for
subjects enrolled in Japan.]

Approved for marketing
Treatment IND/Protocol
Acute Myeloid Leukemia (AML)
FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Drug: gilteritinib

oral
Other Name: ASP2215

Eligibility Criteria

Inclusion Criteria:

- Subject is considered an adult according to local regulation at the time of signing
informed consent.

- Subject has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome
(MDS) or therapy-related AML according to World Health Organization (WHO)
classification.

- Subject has presence of the FLT3-mutated relapsed or refractory AML or FLT3-mutated
AML in CRc (CR, CRi, CRp) with MRD in bone marrow or peripheral blood. [Specific to
investigational sites in Japan: FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD
subjects will not be included.]

- Subject has refractory or relapsed AML (with or without hematopoietic stem cell
transplant [HSCT]) or AML in CRc (CR, CRi, CRp) with MRD by flow cytometry or genetic
testing for the FLT3 mutation after induction/consolidation regimen or HSCT. [Specific
to investigational sites in Japan: FLT3-mutated AML in CRc (CR, CRi, CRp) with MRD
subjects will not be included.]

- Subject must wait for at least 5 half-lives after stopping therapy with any
investigational agent and before starting ASP2215.

- Subject must meet the following criteria as indicated on clinical laboratory tests:

- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x
institutional upper limit of normal (ULN)

- Serum total bilirubin ≤ 2.5 mg/dL, except for subjects with Gilbert's syndrome

- Serum potassium and serum magnesium ≥ institutional lower limit of normal (LLN).

- Subject is able to tolerate oral administration of study drug.

- Subject who has developed overall grades II-IV acute graft-versus-host disease (GVHD)
must satisfy the following criteria:

- No requirement of > 0.5 mg/kg of prednisone (or equivalent) daily dose within 1
week of enrollment

- No escalation of immunosuppression in terms of increase of corticosteroids or
addition of new agent/modality in prior 2 weeks (note that increasing calcineurin
inhibitors or sirolimus to achieve therapeutic trough levels is allowed)

- Female subject must either:

- Be of nonchildbearing potential:

- Postmenopausal (defined as at least 1 year without any menses) prior to
screening, or

- Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy,
bilateral oophorectomy) at least 1 month prior to screening.

- Or, if of childbearing potential,

- Agree not to try to become pregnant during the study and for at least 180 days
after the final study drug administration

- And have a negative urine pregnancy test at screening

- And, if heterosexually active, agree to use consistently 2 forms of effective
contraception per locally accepted standards (1 of which must be a barrier
method) starting at screening and throughout the study period and for at least
180 days after the final study drug administration.

- Female subject must agree not to breastfeed or donate ova starting at screening and
throughout the study period, and for at least 180 days after the final study drug
administration.

- Male subject (even if surgically sterilized) and partners who are women of
childbearing potential must agree to practice 2 forms of effective contraception per
locally accepted standards

(1 of which must be a barrier method), starting at screening and throughout the study
period and for 120 days after the final study drug administration.

- Male subject must not donate sperm starting at screening and throughout the study
period and for 120 days after the final study drug administration.

- Subject agrees not to participate in another interventional study for AML while on
treatment.

- Subject who has a diagnosis of HIV may be enrolled as long as the disease is under
control on antiretroviral therapy. Precautions should be taken to modify highly active
antiretroviral therapy (HAART) regimen to minimize drug interactions.

- There is no comparable or satisfactory alternative therapy to treat the subject's AML.

Exclusion Criteria:

- Subject is eligible to participate in an ongoing clinical study of ASP2215; or has
previously participated in a randomized clinical study of ASP2215 with a primary
endpoint of overall survival that is not closed for efficacy.

- Subject with QTcF > 450 ms at screening based on local reading.

- Subject with a known history of Long QT Syndrome at screening.

- Subject was diagnosed with acute promyelocytic leukemia (APL).

- Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).

- Subject has clinically significant coagulation abnormality unless secondary to AML.

- Subject has active hepatitis B or C or an active hepatic disorder.

- Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias,
electrocardiographic evidence of acute ischemia, or New York Heart Association (NYHA)
Class IV heart failure.

- Subject requires treatment with concomitant drugs that are strong inducers of CYP3A.

- Subject has any condition which makes the subject unsuitable for study participation.

- Subject has hypersensitivity to any of the study drug components.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Canada
Japan
United States
Locations

UCLA
Los Angeles, California, United States

Rocky Mountain Cancer Center-M
Aurora, Colorado, United States

Memorial Healthcare System
Pembroke Pines, Florida, United States

Northside Hospital
Atlanta, Georgia, United States

Georgia Cancer Center at Augusta University
Augusta, Georgia, United States

Northwestern University Medical Center
Chicago, Illinois, United States

University of Chicago
Chicago, Illinois, United States

Indiana Blood and Marrow Transplantation at Franciscan Health Indianapolis
Indianapolis, Indiana, United States

Norton Cancer Institute
Louisville, Kentucky, United States

Tulane University
New Orleans, Louisiana, United States

University of Maryland Medical Center
Baltimore, Maryland, United States

Johns Hopkins Hospital
Baltimore, Maryland, United States

The Sidney Kimmel Comprehensive Cancer Center -Johns Hopkins University
Baltimore, Maryland, United States

Massachusetts General Hospital
Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Dana Farber Cancer Institute
Boston, Massachusetts, United States

West Michigan Regional Cancer Center
Kalamazoo, Michigan, United States

Washington University School of Medicine
Saint Louis, Missouri, United States

New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States

Roswell Park Cancer Institute
Buffalo, New York, United States

Memorial Sloan Kettering
New York, New York, United States

Weill Cornell Medical College
New York, New York, United States

Duke University Medical Center
Durham, North Carolina, United States

Wake Forest Baptist Hospital
Winston-Salem, North Carolina, United States

Ohio State University
Columbus, Ohio, United States

Providence Portland Medical Center
Portland, Oregon, United States

Penn State Hershey Medical Center
Hershey, Pennsylvania, United States

Thomas Jefferson University
Philadelphia, Pennsylvania, United States

UPCI
Pittsburgh, Pennsylvania, United States

Vanderbilt University
Nashville, Tennessee, United States

Huntsman Cancer Institute University of Utah
Salt Lake City, Utah, United States

WVU Medicine Cancer
Morgantown, West Virginia, United States

Site CA15002
Halifax, Nova Scotia, Canada

Site CA15003
Toronto, Ontario, Canada

Site CA15001
Montreal, Quebec, Canada

Site CA15005
Vancouver, Canada

Site JP81001
Nagoya, Aichi, Japan

Site JP81002
Shinagawa-ku, Tokyo, Japan

Site JP81003
Fukuoka, Japan

Medical Director, Study Director
Astellas Pharma Global Development, Inc.

Astellas Pharma Global Development, Inc.
NCT Number
Keywords
Acute myeloid leukemia (AML)
FMS-like Tyrosine kinase-3 (FLT3) mutations
gilteritinib
Expanded Access
ASP2215
MeSH Terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasm, Residual